Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Daniel Staiculescu"'
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Multikinase inhibitors (MKIs) have been the only first-line treatment for advanced hepatocellular carcinoma (HCC) for more than a decade, until the approval of immune checkpoint inhibitors (ICIs). Moreover, the combination regimen of atezolizumab (an
Externí odkaz:
https://doaj.org/article/cc5a3417a4b746c8bace04b2b7c182b8
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Pancreatic leiomyosarcoma (PL) is a very rare, malignant neoplasm with a very poor prognosis. Here, we examine a novel case of PL with schistosomiasis hematobia. The patient had been initially misdiagnosed by the first magnetic resonance imaging (MRI
Externí odkaz:
https://doaj.org/article/7ac63f4dc0e247828087e73ac7da1c32
Autor:
Alexander Quaas, Lipika Goyal, Andrew X Zhu, Mark Cobbold, Dan G Duda, Rakesh K Jain, Kohei Shigeta, Aya Matsui, Hiroto Kikuchi, Sebastian Klein, Emilie Mamessier, Ivy X Chen, Shuichi Aoki, Shuji Kitahara, Koetsu Inoue, Ayako Shigeta, Tai Hato, Rakesh R Ramjiawan, Daniel Staiculescu, Dieter Zopf, Lukas Fiebig, Gabriela S Hobbs, Simona Dima, Irinel Popescu, Peigen Huang, Lance L Munn
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background and purpose Combining inhibitors of vascular endothelial growth factor and the programmed cell death protein 1 (PD1) pathway has shown efficacy in multiple cancers, but the disease-specific and agent-specific mechanisms of benefit remain u
Externí odkaz:
https://doaj.org/article/3a16c10d09a0429d990a0dd5f6981ee3
Autor:
Jiang, Chen, Shi, Jiang, Huijiang, Shao, Bixia, Li, Tong, Ji, Daniel, Staiculescu, Jiayan, He, Jie, Zhao, Liuxin, Cai, Xiao, Liang, Junjie, Xu, Xiujun, Cai
Publikováno v:
Science China Life Sciences. 65:1998-2016
The treatment of hepatocellular carcinoma (HCC) has been dominated by multikinase inhibitors for more than a decade. However, drug resistance can severely restrict the efficacy of these drugs. Using CRISPR/CAS9 genome library screening, we evaluated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4ff39777a7c77c417e3ddbb940dc305
https://doi.org/10.1007/s11427-021-2067-7
https://doi.org/10.1007/s11427-021-2067-7
Autor:
Hiroto Kikuchi, Aya Matsui, Satoru Morita, Zohreh Amoozgar, Koetsu Inoue, Zhiping Ruan, Daniel Staiculescu, Jeffrey Sum-Lung Wong, Peigen Huang, Thomas Yau, Rakesh K Jain, Dan G Duda
Publikováno v:
J Natl Cancer Inst
Immune checkpoint blockade combined with antiangiogenic therapy induces vascular normalization and antitumor immunity and is efficacious in hepatocellular carcinoma (HCC); but whether and how initial immunotherapy affects the efficacy of subsequent a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd3937d0e38116765fd9f7a5d12bebab
https://doi.org/10.1093/jnci/djac051
https://doi.org/10.1093/jnci/djac051
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
Pancreatic leiomyosarcoma (PL) is a very rare, malignant neoplasm with a very poor prognosis. Here, we examine a novel case of PL with schistosomiasis hematobia. The patient had been initially misdiagnosed by the first magnetic resonance imaging (MRI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93f89bc22e152f9808fa588a2ef08520
http://europepmc.org/articles/PMC8045707
http://europepmc.org/articles/PMC8045707
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Lu Chen, Jiang Chen, Jiahao Hu, Mingyu Chen, Jiacheng Lin, Daniel Staiculescu, Sarun Juengpanich, Win Topatana, Xiu-Jun Cai, Shijie Li, Jiasheng Cao
Publikováno v:
International journal of cancerReferences. 147(7)
Hepatocellular carcinoma (HCC) remains as one of the major causes of cancer-related mortality, despite the recent development of new therapeutic options. Regorafenib, an oral multikinase inhibitor, is the first systemic therapy that has a survival be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44957d5dc48fc8c977e261e53cb5ecc5
https://pubmed.ncbi.nlm.nih.gov/32162677
https://pubmed.ncbi.nlm.nih.gov/32162677
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Multikinase inhibitors (MKIs) have been the only first-line treatment for advanced hepatocellular carcinoma (HCC) for more than a decade, until the approval of immune checkpoint inhibitors (ICIs). Moreover, the combination regimen of atezolizumab (an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcc344fc0dccc65d429b3b64a963cbf6
https://doi.org/10.1177/17588359211018026
https://doi.org/10.1177/17588359211018026
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.